Lenovo™ Sees Intelligence Transforming Everything at MWC 2018, From Devices to Data Center
Today, at MWC 2018, Lenovo reinforced its 2018 vision for technology innovations, moving its core strategy to Augmented Intelligence.
With its roots in the PC space, Lenovo has created one of the most complete collections of smart AI devices, giving it a unique advantage to provide the three key elements of Intelligence: Data, Computing Power and Algorithm.
Through new AR, VR and voice-activated technologies demonstrated at the show, Lenovo gives you powerful new ways to live, work and play. From intuitive new voice-enabled Yoga™ 2-in-1 laptops launched today, to transformative Moto Mods, to advanced data center solutions, Lenovo makes all the critical human connections to AI, from devices to data center.
A Different Smartphone Experience
At MWC, Motorola will be illustrating how it continues to challenge the industry with premium smartphone features at great value price points, and how innovation lives in our DNA with transformative Moto Mods that help you monitor your wellness, among other things. The Motorola Health Mod will be showcased, which allows you to easily measure five vital signs including accurate systolic and diastolic blood pressure, all via your moto z device.
Motorola will be sharing insights around its recently released global Phone-Life Balance Study which has been developed in partnership with Dr. Nancy Etcoff, renowned expert in Mind-Brain Behavior and the Science of Happiness at Harvard. The study identifies problematic behaviors that are impacting relationships with others and ourselves and shows how people are putting their phones before those they care about, with the most alarming findings tied to younger generations who have grown up in a digital world.
Motorola believes technology should enrich our lives, rather than distract from them and is offering intelligent solutions to help people manage their phone life balance. This includes a partnership with SPACE, an app that helps to make you more mindful of your phone usage, and Moto Experiences that support more intuitive mobile interactions.
A Different Approach to Voice
Lenovo’s PC and Smart Devices business is developing new products to transform commercial and consumer experiences through Augmented Intelligence.
At MWC, Lenovo will be introducing the new Yoga 730 (in 13-inch and 15-inch models) and the new 14-inch Yoga 530 – the latest additions to its 2-in-1 family designed for the mobile generation. The new Windows 10-based convertibles feature modern designs, powerful laptop performance and tablet portability that have made the Lenovo Yoga an iconic premium laptop brand since it first pioneered the convertible form factor. The new Yoga 730 harnesses the power of AI to give you intelligent assistance hands-free. With both Cortana and Alexa built-in, it offers more choice and recognizes voice commands from across the room.1
Lenovo’s new trio of ruggedized Lenovo 500e, 300e 2-in-1’s and 100e Chromebooks built for education are now available for consumers. Beyond the protective designs to guard against spills and drops the 300e Chromebook features Lenovo Enhanced Touch technology that allows the use of everyday objects to interact with the screen and the 500e Chromebook provides an EMR™ Pen with Google®’s innovative near lag-free algorithms for writing and sketching.
For smarter living, the new Lenovo Smart Display announced at CES 2018 makes using technology at home more convenient, intuitive and shared. It combines the voice capability of the Google Assistant™ with a vibrant, full HD touchscreen display.2 As the command hub for connected smart home devices, from lighting to heating and more, it can be controlled with just your voice or a quick glance at the display.
A Different Way to Experience Reality
Also launched at CES 2018, Lenovo will showcase how Augmented Intelligence continues to make its devices different and more immersive. The Lenovo Mirage™ Solo standalone VR headset and Lenovo Mirage Camera, a VR180 camera, lets you to create and consume your own VR content using Daydream™, Google’s mobile VR platform, while Star Wars™: Jedi Challenges with its Lenovo Mirage AR headset and Lightsaber controller breaks the boundaries of what’s possible by letting fans experience Jedi training in AR.
A Different Way to Improve the World
Lenovo’s Data Center Group continues to power the Intelligence Revolution by expanding into two new segments in Telecommunications and IoT.
As innovations in mobile and smart devices rapidly grow, the telecom industry is undergoing massive changes with 5G networks. Lenovo is uniquely positioned to disrupt the traditional telecom installed base and provide a seamless transition for communication service providers to the software defined world.
Lenovo is launching a performance optimized offering based on Lenovo ThinkSystem SR650/SR630 servers and switches, Red Hat OpenStack Platform, and Mellanox ConnectX-4 NICs for accelerated packet processing. In addition, Lenovo is joining the ‘Intel Select Solution for NFV’ program and offering a solution specially optimized for encryption and compression based NFV workloads. The solution is comprised of Intel QuickAssist Technology (QAT) and Intel XXV710 NIC enabled on Lenovo SR650/SR630 servers.
Leveraging its #1 position in x86 server reliability3, Lenovo will also demo the industry's first 5G-ready base station with software and virtualized implementation of the centralized and distributed units (CU/DU) – made possible through customer-led, joint collaboration with China Mobile.
Demonstrations of Lenovo’s ‘device to datacenter’ solutions can be seen at Mobile World Congress in Barcelona, February 26 – March 1 at the Lenovo Showcase in Hall 3, Space 3N30. In the Intel booth, Lenovo will showcase a ‘self-optimizing 5G network’ solution based on Lenovo ThinkSystem SR650 servers.
Pricing and Availability
See http://news.lenovo.com/MWC2018 for information about pricing and availability for products.
- Say Hello to the New Lenovo™ Yoga™ 730 and 530
- Lenovo’s Ruggedized Chromebook Trio Adds New Touch and Pen
- Motorola Study Shows Alarming Results That Confirm Need for Better Phone-Life Balance
- Lenovo Data Center Group Further Accelerates Telecommunication Infrastructure and Internet of Things Focus
1 Cortana and Alexa are available on the Yoga 730 with far-field voice-recognition technology supporting up to 4 meters away and in standby mode. Alexa capability is expected to be available in the US, Canada, UK and Germany. List of countries may expand over time.
2 FHD touchscreen display is available on the Lenovo Smart Display 10-inch model.
LENOVO, LENOVO MIRAGE and YOGA are trademarks of Lenovo. GOOGLE, GOOGLE ASSISTANT and DAYDREAM are trademarks of Google, Inc. STAR WARS and related properties are trademarks and/or copyrights, in the United States and other countries, of Lucasfilm Ltd. and/or its affiliates. © & TM Lucasfilm Ltd. EMR is a trademark of Wacom Co., Ltd. ©2018, Lenovo Group Limited.
Lenovo (HKSE: 992) (ADR: LNVGY) is a US$43 billion global Fortune 500 company and a leader in providing innovative consumer, commercial, and data center technology. Our portfolio of high-quality, secure products and services covers PCs (including the legendary Think and multimode Yoga brands), workstations, servers, storage, networking, software (including ThinkSystem and ThinkAgile solutions), smart TVs and a family of mobile products like smartphones (including the Motorola brand), tablets and apps. Join us on LinkedIn, follow us on Facebook or Twitter (@Lenovo) or visit us at http://www.lenovo.com/.
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Octapharma announces approval of new Nuwiq® product strengths in Europe, increasing dosing flexibility for patients with haemophilia A18.6.2018 07:06 | Pressemelding
Octapharma announced today that the European Medicines Agency (EMA) has approved an extension of marketing authorisation for its human cell line-derived recombinant factor VIII (rFVIII) product, Nuwiq®. New single dose vial strengths of 2500, 3000 and 4000 International Units (IU) will be available in Europe, in addition to the current strengths of 250, 500, 1000 and 2000 IU. The new Nuwiq® vial strengths have been available in the US since September last year, following approval by the FDA. Nuwiq® is indicated in adults and children of all ages for on-demand treatment and prophylaxis, including during surgery, to prevent and control bleeding episodes in patients with haemophilia A. This expanded array of vial strengths has the potential to increase treatment options for patients with haemophilia A by improving dosing flexibility. Patients who previously required more than one vial per infusion may be able to reduce the number of vials needed. Nuwiq® is the only rFVIII available in an
STATS and SpokeHub Partner to Power Deeper, More Meaningful Conversations Around the 2018 FIFA World Cup18.6.2018 07:00 | Pressemelding
Today, STATS, the worldwide leader in sports data and intelligence, and SpokeHub announced a new partnership to bring STATS Insights to SpokeHub’s social engagement platform, connecting worldwide World Cup football (soccer) fans with content that is more impactful. Download the app today to see the match scores, player insights, and engage with World Cup fans everywhere! STATS Insights leverages more than 37 years of research experience to deliver deep historical and comparative statistical insights, play-by-play descriptions and in-game trends based on events as they happen in the match. Before, during and after each match, SpokeHub will harness STATS Insights to amplify conversations among World Cup football communities. During the game, live Insights will deliver trends on players and teams based on in-game events, statistics and milestones. “No sporting event gets global attention like the World Cup, and every fan is looking for deeper analysis around their favorite teams and playe
Celltrion Completes Resubmission to FDA for Proposed Trastuzumab Biosimilar18.6.2018 02:53 | Pressemelding
Celltrion (KRX:068270) has made a resubmission to the FDA (U.S. Food and Drug Administration) to obtain its marketing approval for CT-P6, a proposed mAb biosimilar to Herceptin® (trastuzumab). Celltrion submitted its abbreviated Biologics License Applications (aBLAs) for CT-P10 and CT-P6 to the FDA in April and May of last year, respectively. However, it received CRLs (complete response letters) from the FDA related to the warning letter issued by the FDA in January 2018, related to the manufacturing facility in Incheon, South Korea. Celltrion had completed the resubmission for the approval of CT-P10, a proposed biosimilar to Rituxan® (rituximab) last month. In accordance with FDA regulations, the approval procedure will be usually finalized within six months from the resubmission, so Celltrion expects the approval for the U.S. market of the two proposed biosimilars within this calendar year. FDA has notified Celltrion of its re-inspection schedule regarding regular audit results, and
CES Asia: Innovation at the Speed of 5G15.6.2018 14:59 | Pressemelding
CES Asia® 2018 wrapped today with the rapid pace of global innovation front and center over the show’s three day duration. The next stage of technology advancements were showcased across vehicle tech, robotics, artificial intelligence (AI), virtual and augmented reality, digital health and more. The event, 24 percent larger than last year in terms of footprint, cemented itself as the place to fully experience how the pace of technology is accelerating globally. CES Asia, the premier event for tech innovation in the Asian marketplace, will return to Shanghai, China, June 11-13, 2019. “5G and AI are igniting growth across the entire tech ecosystem changing the way we interact with technology and the world around us,” said Gary Shapiro, president and CEO, Consumer Technology Association (CTA)™. “It’s incredible to see technology refining and reinventing itself at such a fast pace. Just six months ago we were at CES with life-altering tech all around us. This week, I saw that technology re
bluebird bio Presents New Data from Northstar (HGB-204) and Northstar-2 (HGB-207) Studies of LentiGlobin™ Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia at Annual Congress of the European Hematology Association15.6.2018 10:00 | Pressemelding
bluebird bio, Inc. (Nasdaq: BLUE) announced that new data from the completed Phase 1/2 Northstar (HGB-204) study in adolescents and adults with transfusion-dependent β-thalassemia (TDT) and any genotype, and its ongoing, Phase 3 Northstar-2 (HGB-207) multicenter clinical study of LentiGlobin™ investigational gene therapy in patients with TDT and non-β0/β0 genotypes, will be presented in an oral session on June 16 at the 23rd Annual Congress of the European Hematology Association by Franco Locatelli, M.D., Ph.D., of the IRCCS Ospedale Pediatrico Bambino Gesù of Rome, Italy. “The maturing data from HGB-204 and HGB-207 suggest that one-time treatment with LentiGlobin may address the underlying genetic cause of TDT. With our refined manufacturing process, the majority of patients with TDT and non-β0/β0 genotypes are transfusion-free and producing total hemoglobin at normal or near-normal levels,” said David Davidson, M.D., chief medical officer, bluebird bio. “We are on track to submit a m
bluebird bio Announces New Interim Data from Phase 1 (HGB-206) Study of LentiGlobin™ Gene Therapy in Patients with Severe Sickle Cell Disease at Annual Congress of the European Hematology Association15.6.2018 10:00 | Pressemelding
bluebird bio, Inc. (Nasdaq: BLUE) today announced new interim data from the ongoing HGB-206 Phase 1 multicenter clinical study of LentiGlobin investigational gene therapy in patients with severe sickle cell disease (SCD) will be presented in an oral presentation on Saturday, June 16 at the 23rd Congress of the European Hematology Association (EHA) by Julie Kanter, M.D., Medical University of South Carolina, Charleston, South Carolina. “The consistent production of increased amounts of anti-sickling HbAT87Q in the Group C patients reflects the substantial positive impact of the changes introduced with the amended HGB-206 study protocol and refined manufacturing process. All four Group C patients with greater than or equal to three months follow-up are making over 30 percent anti-sickling HbAT87Q. The first patient treated, now with six months of follow-up, is producing over 60 percent anti-sickling HbAT87Q with a normal total hemoglobin level of 14.2 g/dL,” said David Davidson, M.D., ch